免疫检查点抑制剂相关皮肤不良反应的管理:系统综述
该系统综述检索2010至2020年文献,纳入138项研究、879例免疫检查点抑制剂相关皮肤不良反应(cirAEs),涵盖斑丘疹、瘙痒、苔藓样、免疫大疱性等亚型;治疗包括局部/全身糖皮质激素、保类固醇药物及停用免疫治疗,各亚型有独特处理选项。
要点
- cirAEs亚型多样,包括斑丘疹、瘙痒、苔藓样、免疫大疱性、银屑病样等。
- 治疗选项包括局部/全身糖皮质激素、保类固醇药物及停用免疫治疗。
- 各亚型有超出当前指南的独特治疗选择,需进一步研究亚型差异。
核心结论
- 免疫检查点抑制剂治疗与多种皮肤毒性相关,各亚型有独特的治疗选择,超出当前已发表指南。
研究设计与样本
- 系统综述,检索PubMed、Embase、Web of Science和Google Scholar(2020年6月26日),限2010至2020年英文文献,最终纳入138项研究(87项来自检索,51项来自参考文献),共报告879例cirAEs。
主要发现
- cirAEs亚型包括斑丘疹、瘙痒、苔藓样、免疫大疱性、银屑病样、肉芽肿性、多形红斑或Stevens-Johnson综合征、伴嗜酸性粒细胞增多和系统症状的药疹、结缔组织病、毛发、口腔及杂类。
- 治疗方法包括局部糖皮质激素、全身糖皮质激素、保类固醇药物以及中断或停止免疫治疗的组合。
临床怎么用
- 临床管理cirAEs时,应根据亚型选择局部/全身糖皮质激素、保类固醇药物或停用免疫治疗等个体化方案。
局限性
- 现有文献多为单中心小病例系列,缺乏大规模前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There exists a paucity of literature that summarizes the effective management of cutaneous immune-related adverse events (cirAEs) in patients with cancer who are receiving immune checkpoint inhibitors (ICIs). Most published articles are small case series from a single institution. To our knowledge, the spectrum of possible treatments has not been systematically reviewed to highlight the breadth of options when caring for patients with cirAEs. OBJECTIVE: To further characterize the development of subtypes of cirAEs in patients with cancer treated with ICIs and provide recommendations on optimal treatment regimens based on the current literature. EVIDENCE REVIEW: A search was performed in PubMed, Embase European, Web of Science, and Google Scholar on June 26, 2020, according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines, limited to the years 2010 to 2020. Articles that met predetermined inclusion criteria (published between January 1, 2010, and June 1, 2020; written in the English language; and original articles, brief reports, case reports, and research letters that reported primarily on cirAE management) were selected, and data were abstracted. Articles that met the scope of the review were also added from reference lists. When possible, the results of studies that addressed a similar question were combined quantitatively. FINDINGS: In total, 138 studies (87 from the aforementioned literature search and 51 additional studies pulled from the reference lists of included articles) were included that reported on 879 cirAEs. The subtypes of cirAEs included maculopapular, pruritus, lichenoid, immunobullous, psoriasiform, granulomatous, erythema multiforme or Stevens Johnson Syndrome, drug rash with eosinophilia and systemic symptoms, connective tissue disease, hair, oral, and miscellaneous. Treatments for cirAEs included a combination of topical corticosteroids, systemic corticosteroids, steroid-sparing agents, and discontinuation or cessation of immunotherapy. CONCLUSIONS AND RELEVANCE: This systematic review found that treatment with ICIs was associated with many types of skin toxic effects, each with unique treatment options beyond current published guidelines. Further research into key differences between subtypes is critical to improve the care provided to patients with cancer.
引用
- Nadelmann ER, Yeh JE, Chen ST, et al. Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review. JAMA Oncol. 2022. PMID: 34709352. doi:10.1001/jamaoncol.2021.4318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。